DCF Tool


Pediatrix Medical Group Inc – General Medical and Surgical Hospitals
mednax is a physician-led health solutions partner providing the highest quality patient care through our national network of nearly 3,000 physicians. our physician practices and business professionals are passionate about taking great care of patients, continually optimizing performance and helping providers overcome healthcare’s quality, financial and administrative complexities. physicians and advanced practitioners practicing as part of mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research to enhance patient outcomes and provide high-quality, cost-effective care. the company was founded in 1979, and today, through its affiliated professional corporations, mednax provides services through a network of more than 3,200 physicians in all 50 states and puerto rico. in addition to its national physician network, mednax provides services to healthcare facilities and physicians in
Analysis Results
Intrinsic Value $39.20
Latest Price $12.32
Relative Value 69% undervalued
Thoughts on this result? Let us know.
Cash Flow (Millions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of -4.0%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 7.5%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of -4.0%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 238 221
2024 228 197
2025 219 176
2026 210 157
2027 202 140
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 3710 million. This corresponds to a present value of 2400 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 891 million. Adding in the terminal value gives a total present value of 3290 million.

There are presently 83.9 million outstanding shares, so the intrinsic value per share is 39.2.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 427,989,000
Current Cash 103,063,000
Current Liabilities 426,983,000
Current Debt 14,898,000
Non-Cash Working Capital (NCWC) -87,159,000
Change in NCWC -15,741,000
EBIT 201,722,000
Tax Provision 18,806,000
Depreciation and Amortization 35,636,000
Capital Expenditure -29,708,000
Unlevered Free Cash Flow 145,287,592
Current Assets 840,564,000
Current Cash 487,106,000
Current Liabilities 427,366,000
Current Debt 2,490,000
Non-Cash Working Capital (NCWC) -71,418,000
Change in NCWC 50,063,000
EBIT 219,650,000
Tax Provision 27,241,000
Depreciation and Amortization 32,147,000
Capital Expenditure -32,249,000
Unlevered Free Cash Flow 225,363,612
Current Assets 1,549,348,000
Current Cash 1,228,713,000
Current Liabilities 444,335,000
Current Debt 2,219,000
Non-Cash Working Capital (NCWC) -121,481,000
Change in NCWC -124,023,000
EBIT 173,518,000
Tax Provision 16,728,000
Depreciation and Amortization 28,441,000
Capital Expenditure -28,788,000
Unlevered Free Cash Flow 32,420,000
Current Assets 731,507,000
Current Cash 187,277,000
Current Liabilities 541,818,000
Current Debt 130,000
Non-Cash Working Capital (NCWC) 2,542,000
Change in NCWC -96,259,000
EBIT 416,274,000
Tax Provision -91,886,000
Depreciation and Amortization 78,860,000
Capital Expenditure -31,881,000
Unlevered Free Cash Flow 366,994,000
Current Assets 657,409,000
Current Cash 58,668,000
Current Liabilities 500,193,000
Current Debt 253,000
Non-Cash Working Capital (NCWC) 98,801,000
Change in NCWC 72,082,000
EBIT 452,673,000
Tax Provision 100,210,000
Depreciation and Amortization 111,281,000
Capital Expenditure -48,868,000
Unlevered Free Cash Flow 464,181,110
Current Assets 627,235,000
Current Cash 70,492,000
Current Liabilities 531,425,000
Current Debt 1,401,000
Non-Cash Working Capital (NCWC) 26,719,000
Change in NCWC -66,530,000
EBIT 481,028,000
Tax Provision 90,050,000
Depreciation and Amortization 102,879,000
Capital Expenditure -49,309,000
Unlevered Free Cash Flow 362,526,456
Current Assets 587,128,000
Current Cash 66,984,000
Current Liabilities 448,949,000
Current Debt 22,054,000
Non-Cash Working Capital (NCWC) 93,249,000
Change in NCWC 42,793,000
EBIT 574,872,000
Tax Provision 189,203,000
Depreciation and Amortization 89,264,000
Capital Expenditure -39,264,000
Unlevered Free Cash Flow 455,972,281
Current Assets 527,769,000
Current Cash 60,425,000
Current Liabilities 428,771,000
Current Debt 11,883,000
Non-Cash Working Capital (NCWC) 50,456,000
Change in NCWC 43,175,000
EBIT 560,995,000
Tax Provision 204,038,000
Depreciation and Amortization 64,228,000
Capital Expenditure -27,073,000
Unlevered Free Cash Flow 429,247,646
Current Assets 467,052,000
Current Cash 53,963,000
Current Liabilities 416,273,000
Current Debt 10,465,000
Non-Cash Working Capital (NCWC) 7,281,000
Change in NCWC -37,264,000
EBIT 514,779,000
Tax Provision 191,413,000
Depreciation and Amortization 45,990,000
Capital Expenditure -18,061,000
Unlevered Free Cash Flow 311,711,611
Current Assets 408,839,000
Current Cash 37,594,000
Current Liabilities 326,792,000
Current Debt 92,000
Non-Cash Working Capital (NCWC) 44,545,000
Change in NCWC -18,398,000
EBIT 452,131,000
Tax Provision 167,895,000
Depreciation and Amortization 39,966,000
Capital Expenditure -15,654,000
Unlevered Free Cash Flow 288,757,527
Current Assets 359,044,000
Current Cash 27,864,000
Current Liabilities 268,338,000
Current Debt 101,000
Non-Cash Working Capital (NCWC) 62,943,000
Change in NCWC 2,563,000
EBIT 389,520,000
Tax Provision 147,264,000
Depreciation and Amortization 30,816,000
Capital Expenditure -14,495,000
Unlevered Free Cash Flow 260,628,217

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.